Skip to main content
. 2023 Feb 2;15(1):2165390. doi: 10.1080/19420862.2023.2165390

Figure 5.

Figure 5.

Neutralization breath and potency of CAP256.J3LS antibody. (a) Neutralization IC80 of CAP256.J3LS on a 208 global virus panel in comparison with parental antibodies and select HIV-1 antibodies in clinical development. (b) Neutralization IC80 of CAP256.J3LS on a 100 Acute-Early Clade C virus panel. (c) Breadth-IC80 curves of CAP256.J3LS in comparison with parental antibodies and select HIV-1 antibodies in clinical development.